

Pulmonary Arterial Hypertension - Pipeline Insight, 2021

<https://marketpublishers.com/r/PCBE79F0D02EN.html>

Date: July 2021

Pages: 100

Price: US\$ 2,500.00 (Single User License)

ID: PCBE79F0D02EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Pulmonary Arterial Hypertension - Pipeline Insight, 2021," report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Pulmonary Arterial Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Pulmonary Arterial Hypertension Understanding

Pulmonary Arterial Hypertension: Overview

Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels. The tests that are commonly performed to diagnose PAH and rule out other diseases are echocardiography, blood tests, pulmonary function tests, X-rays of the chest, lung blood flow scans, electrocardiography (ECG), and the "6-minute walk test", which measures how far an individual can walk in that time period. Treatment for PAH includes prostaglandins, endothelin receptor antagonists, phosphodiesterase Type 5

inhibitors. Other treatments such as anticoagulants, diuretics, and oxygen may be used to treat PAH as supportive therapies.

'Pulmonary Arterial Hypertension - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Arterial Hypertension pipeline landscape is provided which includes the disease overview and Pulmonary Arterial Hypertension treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Arterial Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Arterial Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Arterial Hypertension.

Pulmonary Arterial Hypertension Emerging Drugs Chapters

This segment of the Pulmonary Arterial Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pulmonary Arterial Hypertension Emerging Drugs

Sotatercept: Acceleron Pharma

Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth

differentiation factor pathway, and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF- β superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trial for the treatment of PAH.

LIQ861: Liquidia Technologies

LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company's novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).

Further product details are provided in the report.....

Pulmonary Arterial Hypertension: Therapeutic Assessment

This segment of the report provides insights about the different Pulmonary Arterial Hypertension drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pulmonary Arterial Hypertension

There are approx. 55+ key companies which are developing the therapies for Pulmonary Arterial Hypertension. The companies which have their Pulmonary Arterial Hypertension drug candidates in the most advanced stage, i.e. Preregistration include, Liquidia Technologies.

Phases

DelveInsight's report covers around 55+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary Arterial Hypertension: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Arterial Hypertension therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Arterial Hypertension drugs.

Pulmonary Arterial Hypertension Report Insights

Pulmonary Arterial Hypertension Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Pulmonary Arterial Hypertension Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Pulmonary Arterial Hypertension drugs?

How many Pulmonary Arterial Hypertension drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Arterial Hypertension?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Arterial Hypertension therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Pulmonary Arterial Hypertension and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Merck Sharp & Dohme

Accelaron Pharma

Liquidia Technologies

Gossamer Bio

Resverlogix

PhaseBio Pharmaceuticals

Pharmosa BioPharm

Complexa

Gmax Biopharm Australia

Mezzion

Radikal Therapeutics

Galectin Therapeutics

Altavant Sciences

Ribomic

Key Products

MK-5475

Sotatercept

LIQ861

GB-002

Apabetalone

PB1046

L-606

CXA-10

GMA-301

Udenafil

R107

Belapectin

Rodatristat ethyl

RBM-011

Contents

- Introduction
- Executive Summary
- Pulmonary Arterial Hypertension: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Pulmonary Arterial Hypertension – DelveInsight's Analytical Perspective
- Late Stage Products (Phase III)
 - Comparative Analysis
- Sotatercept: Acceleron Pharma
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- GB-002: Gossamer Bio
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- Apabetalone: Resverlogix
 - Product Description
 - Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical/Discovery Stage Products
 Comparative Analysis
R107: Radikal Therapeutics
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Pulmonary Arterial Hypertension Key Companies
Pulmonary Arterial Hypertension Key Products
Pulmonary Arterial Hypertension- Unmet Needs
Pulmonary Arterial Hypertension- Market Drivers and Barriers
Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
Pulmonary Arterial Hypertension Analyst Views
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Pulmonary Arterial Hypertension

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Pulmonary Arterial Hypertension

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Pulmonary Arterial Hypertension - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PCBE79F0D02EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PCBE79F0D02EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970